Recruiting Myeloproliferative Neoplasms Studies in Aurora
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptim...
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia ...
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be...
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate re...
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (...
About Myeloproliferative Neoplasms Clinical Trials in Aurora
Myeloproliferative neoplasms (MPNs) are blood cancers in which the bone marrow overproduces red blood cells, platelets, or white blood cells. Types include polycythemia vera, essential thrombocythemia, and myelofibrosis. Treatment depends on the specific type and risk factors.
There are currently 5 myeloproliferative neoplasms clinical trials recruiting participants in Aurora, CO. These studies are seeking a combined 1,770 participants. Research is being sponsored by Kartos Therapeutics, Inc., Swedish Orphan Biovitrum, Karyopharm Therapeutics Inc and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Myeloproliferative Neoplasms Clinical Trials in Aurora — FAQ
Are there myeloproliferative neoplasms clinical trials in Aurora?
Yes, there are 5 myeloproliferative neoplasms clinical trials currently recruiting in Aurora, CO. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Aurora?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you about next steps.
Are clinical trials in Aurora free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Aurora studies also compensate for your time and travel.
What myeloproliferative neoplasms treatments are being tested?
The 5 active trials in Aurora are testing new therapies including novel drugs, biologics, and treatment approaches for myeloproliferative neoplasms.
Data updated March 2, 2026 from ClinicalTrials.gov